NASDAQ:AGTC

Applied Genetic Technologies Competitors

$3.62
-0.18 (-4.74 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.54
Now: $3.62
$3.80
50-Day Range
$3.80
MA: $5.01
$6.04
52-Week Range
$3.54
Now: $3.62
$9.67
Volume1.46 million shs
Average Volume2.90 million shs
Market Capitalization$154.76 million
P/E RatioN/A
Dividend YieldN/A
Beta2.33

Competitors

Applied Genetic Technologies (NASDAQ:AGTC) Vs. MGTX, HARP, VXRT, CGEN, TARS, and AGEN

Should you be buying AGTC stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Applied Genetic Technologies, including MeiraGTx (MGTX), Harpoon Therapeutics (HARP), Vaxart (VXRT), Compugen (CGEN), Tarsus Pharmaceuticals (TARS), and Agenus (AGEN).

MeiraGTx (NASDAQ:MGTX) and Applied Genetic Technologies (NASDAQ:AGTC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Insider and Institutional Ownership

56.4% of MeiraGTx shares are held by institutional investors. Comparatively, 57.9% of Applied Genetic Technologies shares are held by institutional investors. 16.5% of MeiraGTx shares are held by company insiders. Comparatively, 7.5% of Applied Genetic Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares MeiraGTx and Applied Genetic Technologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MeiraGTx$13.29 million46.40$-54,750,000.00($1.65)-8.44
Applied Genetic Technologies$2.45 million63.17$-45,890,000.00($2.17)-1.67

Applied Genetic Technologies has lower revenue, but higher earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Applied Genetic Technologies, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

MeiraGTx has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Comparatively, Applied Genetic Technologies has a beta of 2.33, suggesting that its share price is 133% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for MeiraGTx and Applied Genetic Technologies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MeiraGTx00403.00
Applied Genetic Technologies00603.00

MeiraGTx currently has a consensus price target of $33.00, suggesting a potential upside of 136.90%. Applied Genetic Technologies has a consensus price target of $17.5833, suggesting a potential upside of 385.73%. Given Applied Genetic Technologies' higher possible upside, analysts clearly believe Applied Genetic Technologies is more favorable than MeiraGTx.

Profitability

This table compares MeiraGTx and Applied Genetic Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MeiraGTx-283.20%-29.14%-17.49%
Applied Genetic TechnologiesN/A-73.06%-53.25%

Summary

Applied Genetic Technologies beats MeiraGTx on 8 of the 13 factors compared between the two stocks.

Applied Genetic Technologies (NASDAQ:AGTC) and Harpoon Therapeutics (NASDAQ:HARP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.

Insider and Institutional Ownership

57.9% of Applied Genetic Technologies shares are held by institutional investors. Comparatively, 79.0% of Harpoon Therapeutics shares are held by institutional investors. 7.5% of Applied Genetic Technologies shares are held by insiders. Comparatively, 34.9% of Harpoon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Applied Genetic Technologies and Harpoon Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied Genetic Technologies$2.45 million63.17$-45,890,000.00($2.17)-1.67
Harpoon Therapeutics$5.78 million106.15$-55,570,000.00($2.55)-7.42

Applied Genetic Technologies has higher earnings, but lower revenue than Harpoon Therapeutics. Harpoon Therapeutics is trading at a lower price-to-earnings ratio than Applied Genetic Technologies, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Applied Genetic Technologies has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, Harpoon Therapeutics has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Applied Genetic Technologies and Harpoon Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Applied Genetic Technologies00603.00
Harpoon Therapeutics00803.00

Applied Genetic Technologies presently has a consensus target price of $17.5833, suggesting a potential upside of 385.73%. Harpoon Therapeutics has a consensus target price of $31.75, suggesting a potential upside of 67.72%. Given Applied Genetic Technologies' higher possible upside, research analysts plainly believe Applied Genetic Technologies is more favorable than Harpoon Therapeutics.

Profitability

This table compares Applied Genetic Technologies and Harpoon Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Applied Genetic TechnologiesN/A-73.06%-53.25%
Harpoon Therapeutics-434.74%-68.32%-29.45%

Summary

Harpoon Therapeutics beats Applied Genetic Technologies on 7 of the 13 factors compared between the two stocks.

Applied Genetic Technologies (NASDAQ:AGTC) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.

Insider and Institutional Ownership

57.9% of Applied Genetic Technologies shares are held by institutional investors. Comparatively, 17.9% of Vaxart shares are held by institutional investors. 7.5% of Applied Genetic Technologies shares are held by insiders. Comparatively, 7.3% of Vaxart shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Applied Genetic Technologies and Vaxart's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied Genetic Technologies$2.45 million63.17$-45,890,000.00($2.17)-1.67
Vaxart$9.86 million60.44$-18,650,000.00($0.86)-5.88

Vaxart has higher revenue and earnings than Applied Genetic Technologies. Vaxart is trading at a lower price-to-earnings ratio than Applied Genetic Technologies, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Applied Genetic Technologies has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, Vaxart has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Applied Genetic Technologies and Vaxart, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Applied Genetic Technologies00603.00
Vaxart00203.00

Applied Genetic Technologies presently has a consensus target price of $17.5833, suggesting a potential upside of 385.73%. Vaxart has a consensus target price of $15.00, suggesting a potential upside of 196.44%. Given Applied Genetic Technologies' higher possible upside, research analysts plainly believe Applied Genetic Technologies is more favorable than Vaxart.

Profitability

This table compares Applied Genetic Technologies and Vaxart's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Applied Genetic TechnologiesN/A-73.06%-53.25%
Vaxart-281.50%-84.90%-44.67%

Summary

Applied Genetic Technologies beats Vaxart on 9 of the 13 factors compared between the two stocks.

Applied Genetic Technologies (NASDAQ:AGTC) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.

Insider and Institutional Ownership

57.9% of Applied Genetic Technologies shares are held by institutional investors. Comparatively, 63.4% of Compugen shares are held by institutional investors. 7.5% of Applied Genetic Technologies shares are held by insiders. Comparatively, 9.5% of Compugen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Applied Genetic Technologies and Compugen's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied Genetic Technologies$2.45 million63.17$-45,890,000.00($2.17)-1.67
Compugen$17.80 million31.71$-27,340,000.00($0.43)-19.19

Compugen has higher revenue and earnings than Applied Genetic Technologies. Compugen is trading at a lower price-to-earnings ratio than Applied Genetic Technologies, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Applied Genetic Technologies has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, Compugen has a beta of 2.52, meaning that its stock price is 152% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Applied Genetic Technologies and Compugen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Applied Genetic Technologies00603.00
Compugen00703.00

Applied Genetic Technologies presently has a consensus target price of $17.5833, suggesting a potential upside of 385.73%. Compugen has a consensus target price of $20.2857, suggesting a potential upside of 145.89%. Given Applied Genetic Technologies' higher possible upside, research analysts plainly believe Applied Genetic Technologies is more favorable than Compugen.

Profitability

This table compares Applied Genetic Technologies and Compugen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Applied Genetic TechnologiesN/A-73.06%-53.25%
CompugenN/A-26.98%-23.28%

Summary

Compugen beats Applied Genetic Technologies on 9 of the 12 factors compared between the two stocks.

Applied Genetic Technologies (NASDAQ:AGTC) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.

Insider and Institutional Ownership

57.9% of Applied Genetic Technologies shares are held by institutional investors. 7.5% of Applied Genetic Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Applied Genetic Technologies and Tarsus Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied Genetic Technologies$2.45 million63.17$-45,890,000.00($2.17)-1.67
Tarsus PharmaceuticalsN/AN/AN/AN/AN/A

Tarsus Pharmaceuticals has lower revenue, but higher earnings than Applied Genetic Technologies.

Analyst Ratings

This is a summary of recent ratings and price targets for Applied Genetic Technologies and Tarsus Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Applied Genetic Technologies00603.00
Tarsus Pharmaceuticals00413.20

Applied Genetic Technologies presently has a consensus target price of $17.5833, suggesting a potential upside of 385.73%. Tarsus Pharmaceuticals has a consensus target price of $37.25, suggesting a potential upside of 37.15%. Given Applied Genetic Technologies' higher possible upside, research analysts plainly believe Applied Genetic Technologies is more favorable than Tarsus Pharmaceuticals.

Profitability

This table compares Applied Genetic Technologies and Tarsus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Applied Genetic TechnologiesN/A-73.06%-53.25%
Tarsus PharmaceuticalsN/AN/AN/A

Summary

Applied Genetic Technologies beats Tarsus Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Applied Genetic Technologies (NASDAQ:AGTC) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.

Insider and Institutional Ownership

57.9% of Applied Genetic Technologies shares are held by institutional investors. Comparatively, 53.4% of Agenus shares are held by institutional investors. 7.5% of Applied Genetic Technologies shares are held by insiders. Comparatively, 4.7% of Agenus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Applied Genetic Technologies and Agenus' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied Genetic Technologies$2.45 million63.17$-45,890,000.00($2.17)-1.67
Agenus$150.05 million3.65$-107,660,000.00($0.80)-3.34

Applied Genetic Technologies has higher earnings, but lower revenue than Agenus. Agenus is trading at a lower price-to-earnings ratio than Applied Genetic Technologies, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Applied Genetic Technologies has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, Agenus has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Applied Genetic Technologies and Agenus, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Applied Genetic Technologies00603.00
Agenus00303.00

Applied Genetic Technologies presently has a consensus target price of $17.5833, suggesting a potential upside of 385.73%. Agenus has a consensus target price of $8.00, suggesting a potential upside of 199.07%. Given Applied Genetic Technologies' higher possible upside, research analysts plainly believe Applied Genetic Technologies is more favorable than Agenus.

Profitability

This table compares Applied Genetic Technologies and Agenus' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Applied Genetic TechnologiesN/A-73.06%-53.25%
Agenus-192.56%N/A-97.02%

Summary

Applied Genetic Technologies beats Agenus on 10 of the 13 factors compared between the two stocks.


Applied Genetic Technologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.93-4.3%$616.60 million$13.29 million-9.88
Harpoon Therapeutics logo
HARP
Harpoon Therapeutics
1.5$18.93-1.2%$613.54 million$5.78 million-8.89Insider Selling
Increase in Short Interest
News Coverage
Vaxart logo
VXRT
Vaxart
1.3$5.06-1.0%$595.90 million$9.86 million-8.58
Compugen logo
CGEN
Compugen
1.4$8.25-0.5%$564.47 million$17.80 million-22.30
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.5$27.16-2.5%$556.86 millionN/A0.00
Agenus logo
AGEN
Agenus
1.6$2.68-4.1%$547.53 million$150.05 million-2.45
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.8$8.51-0.8%$528.54 millionN/A-1.24
Solid Biosciences logo
SLDB
Solid Biosciences
1.8$4.81-2.1%$514.08 millionN/A-2.33
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$8.51-4.5%$486.28 million$22.24 million-4.23
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.0$18.57-7.2%$481.15 millionN/A-5.35
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.6$12.24-0.1%$438.87 millionN/A0.00
AVROBIO logo
AVRO
AVROBIO
1.7$10.49-2.2%$436.62 millionN/A-3.18Analyst Downgrade
News Coverage
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$4.81-5.4%$427.32 millionN/A-7.52
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$8.60-2.1%$420.99 million$4.36 million-3.01
Opthea logo
OPT
Opthea
1.5$9.52-5.9%$413.71 millionN/A0.00Gap Down
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.6$8.78-3.1%$398.56 million$147.87 million-2.92
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$8.33-4.2%$348.57 millionN/A0.00
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$12.31-1.6%$343.08 millionN/A0.00News Coverage
Innate Pharma logo
IPHA
Innate Pharma
1.1$4.19-0.7%$330.97 million$96.12 million-12.32
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.6$1.78-2.8%$309.02 million$8.15 million-1.42Increase in Short Interest
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$8.10-0.5%$304.17 million$250,000.00-2.89Analyst Upgrade
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.8$8.18-1.8%$277.31 millionN/A-3.37
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.3$5.20-1.5%$272.20 million$2.91 million-1.81
Surface Oncology logo
SURF
Surface Oncology
1.4$6.45-1.7%$269.15 million$15.36 million-9.77
Codiak BioSciences logo
CDAK
Codiak BioSciences
2.0$11.89-1.2%$261.51 millionN/A0.00Gap Down
Cabaletta Bio logo
CABA
Cabaletta Bio
1.6$10.79-0.4%$259.64 millionN/A-7.88News Coverage
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.7$1.57-8.3%$219.48 million$4.13 million-3.49
Genfit logo
GNFT
Genfit
1.3$4.26-1.6%$189.93 million$45.88 million-2.16
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$1.51-8.6%$183.13 million$29.35 million-1.76
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$5.64-0.0%$180.63 millionN/A-3.52
Gamida Cell logo
GMDA
Gamida Cell
1.4$7.38-1.5%$178.74 millionN/A-5.16News Coverage
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.7$4.67-4.3%$175.84 million$104.39 million-2.85Analyst Report
Protara Therapeutics logo
TARA
Protara Therapeutics
1.8$14.79-3.4%$166.08 millionN/A0.00Increase in Short Interest
INmune Bio logo
INMB
INmune Bio
1.5$11.02-3.2%$164.56 millionN/A-11.36
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$6.22-0.6%$161.74 millionN/A-7.59Analyst Report
Axcella Health logo
AXLA
Axcella Health
1.6$4.25-5.9%$160.18 millionN/A-1.98
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$7.26-1.1%$156.96 millionN/A-1.85News Coverage
Gap Down
X4 Pharmaceuticals logo
XFOR
X4 Pharmaceuticals
1.8$9.00-3.3%$156.46 millionN/A-2.81
Champions Oncology logo
CSBR
Champions Oncology
1.8$11.20-1.5%$149.97 million$32.12 million-86.15
Ayala Pharmaceuticals logo
AYLA
Ayala Pharmaceuticals
1.4$10.50-0.0%$138.29 million$2.33 million0.00News Coverage
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$4.26-3.8%$135.21 million$20,000.000.00
Aziyo Biologics logo
AZYO
Aziyo Biologics
1.4$12.99-0.1%$132.84 millionN/A0.00News Coverage
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
2.0$6.12-1.6%$132.30 millionN/A0.00
Dyadic International logo
DYAI
Dyadic International
1.3$4.74-2.3%$130.61 million$1.68 million-13.94
Genocea Biosciences logo
GNCA
Genocea Biosciences
1.6$2.16-2.8%$115.60 millionN/A-1.49
Brainstorm Cell Therapeutics logo
BCLI
Brainstorm Cell Therapeutics
1.3$3.11-0.0%$111.09 millionN/A-2.96Upcoming Earnings
TRACON Pharmaceuticals logo
TCON
TRACON Pharmaceuticals
1.7$7.08-7.5%$109.59 million$3 million-2.28
La Jolla Pharmaceutical logo
LJPC
La Jolla Pharmaceutical
1.7$3.85-6.0%$105.60 million$23.05 million-1.71
PolarityTE logo
PTE
PolarityTE
1.4$0.86-2.3%$104.20 million$5.65 million-0.52Increase in Short Interest
Cidara Therapeutics logo
CDTX
Cidara Therapeutics
1.6$2.03-2.0%$97.53 million$20.92 million-1.17
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.